363 related articles for article (PubMed ID: 29579321)
1. Long-term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide-based reinduction and maintenance regimens: A 15-year prospective study.
Gill H; Yim R; Lee HKK; Mak V; Lin SY; Kho B; Yip SF; Lau JSM; Li W; Ip HW; Hwang YY; Chan TSY; Tse E; Au WY; Kumana CR; Kwong YL
Cancer; 2018 Jun; 124(11):2316-2326. PubMed ID: 29579321
[TBL] [Abstract][Full Text] [Related]
2. Oral arsenic trioxide, all-trans retinoic acid, and ascorbic acid maintenance after first complete remission in acute promyelocytic leukemia: Long-term results and unique prognostic indicators.
Gill HS; Yim R; Kumana CR; Tse E; Kwong YL
Cancer; 2020 Jul; 126(14):3244-3254. PubMed ID: 32365228
[TBL] [Abstract][Full Text] [Related]
3. Oral arsenic trioxide incorporation into frontline treatment with all-trans retinoic acid and chemotherapy in newly diagnosed acute promyelocytic leukemia: A 5-year prospective study.
Gill H; Kumana CR; Yim R; Hwang YY; Chan TSY; Yip SF; Lee HKK; Mak V; Lau JSM; Chan CC; Kho B; Wong RSM; Li W; Lin SY; Lau CK; Ip HW; Leung RYY; Lam CCK; Kwong YL
Cancer; 2019 Sep; 125(17):3001-3012. PubMed ID: 31090936
[TBL] [Abstract][Full Text] [Related]
4. Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study.
Au WY; Kumana CR; Lee HK; Lin SY; Liu H; Yeung DY; Lau JS; Kwong YL
Blood; 2011 Dec; 118(25):6535-43. PubMed ID: 21998212
[TBL] [Abstract][Full Text] [Related]
5. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
[TBL] [Abstract][Full Text] [Related]
6. Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience.
Cheng Y; Zhang L; Wu J; Lu A; Wang B; Liu G
Eur J Haematol; 2013 Dec; 91(6):483-9. PubMed ID: 24033687
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of early switching to an outpatient therapy model using oral arsenic plus retinoic acid based-regimen in newly diagnosed acute promyelocytic leukemia.
Lou Y; Tong H; Yu W; Wei J; Xu W; Mao L; Jin J
Leuk Res; 2019 Aug; 83():106168. PubMed ID: 31202077
[TBL] [Abstract][Full Text] [Related]
8. Role of hematopoietic stem cell transplantation for relapsed acute promyelocytic leukemia: a retrospective analysis of JALSG-APL97.
Fujita H; Asou N; Iwanaga M; Hyo R; Nomura S; Kiyoi H; Okada M; Inaguma Y; Matsuda M; Yamauchi T; Ohtake S; Izumi T; Nakaseko C; Ishigatsubo Y; Shinagawa K; Takeshita A; Miyazaki Y; Ohnishi K; Miyawaki S; Naoe T;
Cancer Sci; 2013 Oct; 104(10):1339-45. PubMed ID: 23837667
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H
Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214
[TBL] [Abstract][Full Text] [Related]
10. Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. APL Study Group. Acute promyelocytic leukemia.
Thomas X; Dombret H; Cordonnier C; Pigneux A; Gardin C; Guerci A; Vekhoff A; Sadoun A; Stamatoullas A; Fegueux N; Maloisel F; Cahn JY; Reman O; Gratecos N; Berthou C; Huguet F; Kotoucek P; Travade P; Buzyn A; de Revel T; Vilque JP; Naccache P; Chomienne C; Degos L; Fenaux P
Leukemia; 2000 Jun; 14(6):1006-13. PubMed ID: 10865965
[TBL] [Abstract][Full Text] [Related]
11. Autologous transplant remains the preferred therapy for relapsed APL in CR2.
Ganzel C; Mathews V; Alimoghaddam K; Ghavamzadeh A; Kuk D; Devlin S; Wang H; Zhang MJ; Weisdorf D; Douer D; Rowe JM; Polge E; Esteve J; Nagler A; Mohty M; Tallman MS
Bone Marrow Transplant; 2016 Sep; 51(9):1180-3. PubMed ID: 27088379
[TBL] [Abstract][Full Text] [Related]
12. Autologous hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission: outcomes before and after the introduction of arsenic trioxide.
Yanada M; Yano S; Kanamori H; Gotoh M; Emi N; Watakabe K; Kurokawa M; Nishikawa A; Mori T; Tomita N; Murata M; Hashimoto H; Henzan H; Kanda Y; Sawa M; Kohno A; Atsuta Y; Ichinohe T; Takami A
Leuk Lymphoma; 2017 May; 58(5):1061-1067. PubMed ID: 27701911
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of high-risk acute promyelocytic leukemia patients treated with arsenic trioxide (ATO)/all trans retinoic acid (ATRA) based induction and consolidation without maintenance phase: A case Series.
Shah G; Mikhail FM; Bachiasvili K; Vachhani P; Erba HP; Papadantonakis N
Hematol Oncol Stem Cell Ther; 2020 Sep; 13(3):143-146. PubMed ID: 31629725
[TBL] [Abstract][Full Text] [Related]
14. Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA.
Ghavamzadeh A; Jalili M; Rostami S; Yaghmaie M; Aliabadi LS; Mousavi SA; Vaezi M; Fumani HK; Jahani M; Alimoghaddam K
Leuk Res; 2018 Mar; 66():85-88. PubMed ID: 29407588
[TBL] [Abstract][Full Text] [Related]
15. Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients.
Dai CW; Zhang GS; Shen JK; Zheng WL; Pei MF; Xu YX; Cao YX; Yi Y; Yang JJ; Peng HL; Zhong HY; Li RJ
Acta Haematol; 2009; 121(1):1-8. PubMed ID: 19246888
[TBL] [Abstract][Full Text] [Related]
16. Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy.
Cicconi L; Breccia M; Franceschini L; Latagliata R; Molica M; Divona M; Diverio D; Rizzo M; Ottone T; Iaccarino L; Alfonso V; Foa R; Voso MT; Lo-Coco F
Ann Hematol; 2018 Oct; 97(10):1797-1802. PubMed ID: 29951912
[TBL] [Abstract][Full Text] [Related]
17. Acute promyelocytic leukemia (APL): remaining challenges towards a cure for all.
Stahl M; Tallman MS
Leuk Lymphoma; 2019 Dec; 60(13):3107-3115. PubMed ID: 31842650
[TBL] [Abstract][Full Text] [Related]
18. Outcomes and prognostic factors of first relapsed acute promyelocytic leukemia patients undergoing salvage therapy with intravenous arsenic trioxide and chemotherapy.
Lou Y; Suo S; Tong Y; Tong H; Qian W; Meng H; Mai W; Huang J; Yu W; Jin J
Ann Hematol; 2014 Jun; 93(6):941-8. PubMed ID: 24408159
[TBL] [Abstract][Full Text] [Related]
19. Two successful deliveries of healthy children by a young woman diagnosed and treated during induction and relapsed therapy for acute promyelocytic leukemia.
Dang CC; Guan YK; Lau NS; Chan SY
J Oncol Pharm Pract; 2020 Dec; 26(8):2034-2037. PubMed ID: 32279594
[TBL] [Abstract][Full Text] [Related]
20. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
